Posted August 2, 2019
The story I’m going to tell today begins just before the turn of the century. The year is 1999 and Merck has brought a new pain killer onto the market called Vioxx. According to a paper published in the British Medical Journal, since the early development of Vioxx some scientists at Merck were concerned that the drug might adversely affect the cardiovascular system. Despite Merck’s knowledge that Vioxx might increase blood clot formation, none of the intervention studies it did for the FDA in 1998 were designed to evaluate cardiovascular risk. Read more.